Bicycle Therapeutics plc Stock Analysis & AI Score
Bicycle Therapeutics plc (BCYC) has an ST Score of 52.1 (B-), driven by its Forecast (A) and held back by its Momentum (D+). Analysts rate it Buy with a $12.00 price target (+221.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Bicycle Therapeutics plc (BCYC) has an ST Score of 52.1 (B-), driven by its Forecast (A) and held back by its Momentum (D+). Analysts rate it Buy with a $12.00 price target (+221.7% upside).
- Strongest
- ForecastA
- Weakest
- MomentumD+
All factor grades
- ForecastA
- Financial StrengthA-
- ProfitabilityB
- ValuationC+
- GrowthC
- MomentumD+
- Piotroski3/9
Contact
BCYC stock: frequently asked questions
What is BCYC's ST Score?
Bicycle Therapeutics plc (BCYC) has an ST Score of 52.1 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is BCYC a buy, hold, or sell?
Analysts rate BCYC a Buy, with a price target of $12.00 (+221.7% vs the current price). Our ST Score grades it B- (52.1/100). The ST Score is a data-driven signal, not a recommendation.
What are BCYC's factor grades?
Valuation C+, Profitability B, Financial Strength A-, Momentum D+, Growth C, Forecast A.
What is BCYC's valuation grade?
Bicycle Therapeutics plc (BCYC) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is BCYC's growth grade?
Bicycle Therapeutics plc (BCYC) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is BCYC's profitability grade?
Bicycle Therapeutics plc (BCYC) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is BCYC's financial strength grade?
Bicycle Therapeutics plc (BCYC) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for BCYC?
The average analyst price target for Bicycle Therapeutics plc (BCYC) is $12.00 from 21 analysts, which is +221.7% versus the recent price of $3.73.
What is BCYC's Piotroski score?
Bicycle Therapeutics plc (BCYC) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.